Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases

Mediators of Inflammation

Volumn 2013, Issue , 2013, Pages

  Monsalve, Francisco A ^a   Pyarasani, Radha D ^a   Delgado Lopez, Fernando ^b   Moore Carrasco, Rodrigo ^a  

^a UNIVERSIDAD DE TALCA   (Chile)

^b UNIVERSIDAD CATÓLICA DEL MAULE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; FATTY ACID; FIBRIC ACID DERIVATIVE; GLUCOSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIRINIXIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ATHEROSCLEROSIS; CRYSTAL STRUCTURE; DNA BINDING; GENE CONTROL; GLUCOSE METABOLISM; HEART MUSCLE; HUMAN; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INSULIN SENSITIVITY; LIPID METABOLISM; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOSIS; AGONISTS; DRUG EFFECTS; DYSLIPIDEMIAS; METABOLIC SYNDROME X; METABOLISM; DRUG EFFECT; DRUG POTENTIATION; DYSLIPIDEMIA;

DYSLIPIDEMIAS; HUMANS; LIPID METABOLISM; METABOLIC SYNDROME X; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PPAR ALPHA; PPAR DELTA; PPAR-BETA;

EID: 84879283106     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2013/549627     Document Type: Review

References (198)

1. Danaei G., Finucane M. M., Lu Y., Singh G. M., Cowan M. J., Paciorek C. J., Lin J. K., Farzadfar F., Khang Y. H., Stevens G. A., Rao M., Ali M. K., Riley L. M., Robinson C. A., Ezzati M., National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: Systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2 · 7 million participants. The Lancet 2011 378 9785 31 40 2-s2.0-79959936188 10.1016/S0140-6736(11)60679-X
2. World Health Organization, Global Status Report on Noncommunicable Diseases 2010 Geneva, Switzerland
3. Cameron A. J., Shaw J. E., Zimmet P. Z., The metabolic syndrome: prevalence in worldwide populations. Endocrinology and Metabolism Clinics of North America 2004 33 2 351 375 2-s2.0-2542420070 10.1016/j.ecl.2004.03.005
4. Isomaa B., Almgren P., Tuomi T., Forsén B., Lahti K., Nissén M., Taskinen M. R., Groop L., Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001 24 4 683 689 2-s2.0-0034837376
5. Coll T., Rodríguez-Calvo R., Barroso E., Serrano L., Eyre E., Palomer X., Vázquez-Carrera M., Peroxisome proliferator-activated receptor (PPAR) β / δ: a new potential therapeutic target for the treatment of metabolic syndrome. Current Molecular Pharmacology 2009 2 1 46 55 2-s2.0-77449141973 10.2174/1874467210902010046
6. Desvergne B., Wahli W., Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocrine Reviews 1999 20 5 649 688 2-s2.0-0033305213
7. Lee C. H., Olson P., Evans R. M., Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003 144 6 2201 2207 2-s2.0-0037900979 10.1210/en.2003-0288
8. Chawta A., Repa J. J., Evans R. M., Mangelsdorf D. J., Nuclear receptors and lipid physiology: opening the X-files. Science 2001 294 5548 1866 1870 2-s2.0-0035976638 10.1126/science.294.5548.1866
9. De Duve C., Evolution of the peroxisome. Annals of the New York Academy of Sciences 1969 168 2 369 381 10.1111/j.1749-6632.1969.tb43124.x
10. Issemann I., Green S., Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990 347 6294 645 650 2-s2.0-0025132245 10.1038/347645a0
11. Dreyer C., Krey G., Keller H., Givel F., Helftenbein G., Wahli W., Control of the peroxisomal β -oxidation pathway by a novel family of nuclear hormone receptors. Cell 1992 68 5 879 887 2-s2.0-0026517010 10.1016/0092-8674(92)90031-7
12. Feige J. N., Gelman L., Michalik L., Desvergne B., Wahli W., From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Progress in Lipid Research 2006 45 2 120 159 2-s2.0-32644460092 10.1016/j.plipres.2005.12.002
13. Guan Y., Breyer M. D., Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney International 2001 60 1 14 30 2-s2.0-0034951366 10.1046/j.1523-1755.2001.00766.x
14. Fajas L., Debril M. B., Auwerx J., Peroxisome proliferator-activated receptor- γ: from adipogenesis to carcinogenesis. Journal of Molecular Endocrinology 2001 27 1 1 9 2-s2.0-0034892766 10.1677/jme.0.0270001
15. Willson T. M., Lambert M. H., Kliewer S. A., Peroxisome proliferator-activated receptor γ and metabolic disease. Annual Review of Biochemistry 2001 70 341 367 10.1146/annurev.biochem.70.1.341
16. Michalik L., Auwerx J., Berger J. P., Chatterjee V. K., Glass C. K., Gonzalez F. J., Grimaldi P. A., Kadowaki T., Lazar M. A., O'Rahilly S., Palmer C. N. A., Plutzky J., Reddy J. K., Spiegelman B. M., Staels B., Wahli W., International union of pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacological Reviews 2006 58 4 726 741 2-s2.0-33751533892 10.1124/pr.58.4.5
17. Rosen E. D., Walkey C. J., Puigserver P., Spiegelman B. M., Transcriptional regulation of adipogenesis. Genes and Development 2000 14 11 1293 1307 2-s2.0-0034214246
18. Kersten S., Desvergne B., Wahli W., Roles of PPARS in health and disease. Nature 2000 405 6785 421 424 2-s2.0-0034713444 10.1038/35013000
19. Odegaard J. I., Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 2007 447 1116 1120 10.1038/nature05894
20. Hevener A. L., Macrophage PPAR γ is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. The Journal of Clinical Investigation 2007 117 6 1658 1669 10.1172/JCI31561
21. Kersten S., Regulation of nutrient metabolism and inflammation. Results and Problems in Cell Differentiation 2010 52 13 25 2-s2.0-77957736110 10.1007/978-3-642-14426-4-2
22. Werman A., Hollenberg A., Solanes G., Bjørbæk C., Vidal-Puig A. J., Flier J. S., Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor γ (PPAR γ). Differential activity of PPAR γ 1 and -2 isoforms and influence of insulin. The Journal of Biological Chemistry 1997 272 32 20230 20235 2-s2.0-0030877565 10.1074/jbc.272.32.20230
23. Kliewer S. A., Umesono K., Noonan D. J., Heyman R. A., Evans R. M., Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 1992 358 6389 771 774 2-s2.0-0026705751 10.1038/358771a0
24. Berger J., Moller D. E., The mechanisms of action of PPARs. Annual Review of Medicine 2002 53 409 435 10.1146/annurev.med.53.082901.104018
25. Juge-Aubry C., Pernin A., Favez T., Burger A. G., Wahli W., Meier C. A., Desvergne B., DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements: importance of the 5'-flanking region. The Journal of Biological Chemistry 1997 272 40 25252 25259 2-s2.0-0030771852 10.1074/jbc.272.40.25252
26. Lemberger T., Desvergne B., Wahli W., Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annual Review of Cell and Developmental Biology 1996 12 335 363 2-s2.0-0029731662 10.1146/annurev.cellbio.12.1.335
27. Horlein A. J., Naar A. M., Heinzel T., Torchia J., Gloss B., Kurokawa R., Ryan A., Kamei Y., Soderstrom M., Glass C. K., Rosenfeld M. G., Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 1995 377 6548 397 404 2-s2.0-0029132202
28. Chen J. D., Evans R. M., A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 1995 377 6548 454 457 2-s2.0-0029097233
29. Zhu Y., Qi C., Calandra C., Rao M. S., Reddy J. K., Cloning and identification of mouse steroid receptor coactivator-1 (mSRC-1), as a coactivator of peroxisome proliferator-activated receptor γ Gene Expression 1996 6 3 185 195 2-s2.0-0030341454
30. Zhu Y., Qi C., Jain S., Rao M. S., Reddy J. K., Isolation and characterization of PBP, a protein that interacts with peroxisome proliferator-activated receptor. The Journal of Biological Chemistry 1997 272 41 25500 25506 2-s2.0-0030771856 10.1074/jbc.272.41.25500
31. Moras D., Gronemeyer H., The nuclear receptor ligand-binding domain: structure and function. Current Opinion in Cell Biology 1998 10 3 384 391
32. Ricote M., Valledor A. F., Glass C. K., Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: effects on lipid homeostasis, inflammation, and atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 2004 24 2 230 239 2-s2.0-1042286477 10.1161/01.ATV.0000103951.67680.B1
33. Guan Y., Targeting peroxisome proliferator-activated receptors (PPARs) in kidney and urologic disease. Minerva Urologica e Nefrologica 2002 54 2 65 79 2-s2.0-0035997309
34. Scott C. L., Diagnosis, prevention, and intervention for the metabolic syndrome. The American Journal of Cardiology 2003 92 1 35i 42i
35. Ginsberg H. N., Treatment for patients with the metabolic syndrome. The American Journal of Cardiology 2003 91 7 29E 39E 10.1016/S0002-9149(02)03386-6
36. Gurnell M., Savage D. B., Chatterjee V. K., O'Rahilly S., The metabolic syndrome: peroxisome proliferator-activated receptor γ and its therapeutic modulation. The Journal of Clinical Endocrinology & Metabolism 2003 88 6 2412 2421 10.1210/jc.2003-030435
37. Guan Y., Zhang Y., Schneider A., Davis L., Breyer R. M., Breyer D. M., Peroxisome proliferator-activated receptor-gamma activity is associated with renal microvasculature. American Journal of Physiology Renal Physiology 2001 281 6 1036 1046
38. Kliewer S. A., Sundseth S. S., Jones S. A., Brown P. J., Wisely G. B., Koble C. S., Devchand P., Wahli W., Willson T. M., Lenhard J. M., Lehmann J. M., Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ Proceedings of the National Academy of Sciences of the United States of America 1997 94 9 4318 4323 2-s2.0-0006132932 10.1073/pnas.94.9.4318
39. Cowart L. A., Wei S., Hsu M. H., Johnson E. F., Krishna M. U., Falck J. R., Capdevila J. H., The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferator-activated receptor ligands. The Journal of Biological Chemistry 2002 277 38 35105 35112 2-s2.0-0037144475 10.1074/jbc.M201575200
40. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., Fruchart J. C., Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998 98 19 2088 2093 2-s2.0-0032506273
41. Jones A. B., Peroxisome proliferator-activated receptor (PPAR) modulators: diabetes and beyond. Medicinal Research Reviews 2001 21 6 540 552 2-s2.0-0034798741 10.1002/med.1025
42. Leibowitz M. D., Fievet C., Hennuyer N., Peinado-Onsurbe J., Duez H., Bergera J., Cullinan C. A., Sparrow C. P., Baffic J., Berger G. D., Santini C., Marquis R. W., Tolman R. L., Smith R. G., Moller D. E., Auwerx J., Activation of PPAR δ alters lipid metabolism in db/db mice. FEBS Letters 2000 473 3 333 336 10.1016/S0014-5793(00)01554-4
43. Brown P. J., Smith-Oliver T. A., Charifson P. S., Tomkinson N. C. O., Fivush A. M., Sternbach D. D., Wade L. E., Orband-Miller L., Parks D. J., Blanchard S. G., Kliewer S. A., Lehmann J. M., Willson T. M., Identification of peroxisome proliferator-activated receptor ligands from a biased chemical library. Chemistry and Biology 1997 4 12 909 918 2-s2.0-13144283625
44. Shureiqi I., Jiang W., Zuo X., Wu Y., Stimmel J. B., Leesnitzer L. M., Morris J. S., Fan H. Z., Fischer S. M., Lippman S. M., The 15-lipoxygenase-1 product 13- S -hydroxyoctadecadienoic acid down-regulates PPAR- δ to induce apoptosis in colorectal cancer cells. Proceedings of the National Academy of Sciences of the United States of America 2003 100 17 9968 9973 2-s2.0-0042692791 10.1073/pnas.1631086100
45. 2 is a ligand for the adipocyte determination factor PPAR γ Cell 1995 83 5 803 812 2-s2.0-0028972025
46. Nagy L., Tontonoz P., Alvarez J. G. A., Chen H., Evans R. M., Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR γ Cell 1998 93 2 229 240 2-s2.0-0032540325 10.1016/S0092-8674(00)81574-3
47. Tontonoz P., Nagy L., Alvarez J. G. A., Thomazy V. A., Evans R. M., PPAR γ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998 93 2 241 252 2-s2.0-0032540012 10.1016/S0092-8674(00)81575-5
48. Shih C., Chou T., The antiplatelet activity of magnolol is mediated by PPAR- β / γ Biochemical Pharmacology 2012 84 6 793 803 10.1016/j.bcp.2012.06.022
49. Tontonoz P., Spiegelman B. M., Fat and beyond: the diverse biology of PPAR γ Annual Review of Biochemistry 2008 77 289 312 10.1146/annurev. biochem.77.061307.091829
50. Fajas L., Auboeuf D., Raspe E., Schoonjans K., Lefebvre A. M., Saladin R., The organization, promoter analysis, and expression of the human PPAR γ gene. The Journal of Biological Chemistry 2000 275 1873 1877 10.1074/jbc.275.3.1873
51. Fajas L., Fruchart J. C., Auwerx J., PPAR γ 3 mRNA: a distinct PPAR γ mRNA subtype transcribed from an independent promoter. FEBS Letters 1998 438 1-2 55 60 2-s2.0-0032582349 10.1016/S0014-5793(98)01273-3
52. He W., Barak Y., Hevener A., Olson P., Liao D., Le J., Nelson M., Ong E., Olefsky J. M., Evans R. M., Adipose-specific peroxisome proliferator-activated receptor γ knockout causes insulin resistance in fat and liver but not in muscle. Proceedings of the National Academy of Sciences of the United States of America 2003 100 26 15712 15717 2-s2.0-9144229185 10.1073/pnas.2536828100
53. Ricote M., Huang J., Fajas L., Li A., Welch J., Najib J., Witztum J. L., Auwerx J., Palinski W., Glass C. K., Expression of the peroxisome proliferator-activated receptor γ (PPAR γ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proceedings of the National Academy of Sciences of the United States of America 1998 95 13 7614 7619 2-s2.0-0032560545
54. Braissant O., Foufelle F., Scotto C., Dauça M., Wahli W., Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR- α-β and-γ in the adult rat. Endocrinology 1996 137 1 354 366 2-s2.0-0030047806 10.1210/en.137.1.354
55. Rosen E. D., Spiegelman B. M., PPAR γ: a nuclear regulator of metabolism, differentiation, and cell growth. The Journal of Biological Chemistry 2001 276 41 37731 37734 2-s2.0-0035851187
56. Tontonoz P., Spiegelman B. M., Fat and beyond: the diverse biology of PPAR γ Annual Review of Biochemistry 2008 77 289 312 2-s2.0-50649097541 10.1146/annurev.biochem.77.061307.091829
57. Tontonoz P., Hu E., Graves R. A., Budavari A. I., Spiegelman B. M., mPPAR γ 2: tissue-specific regulator of an adipocyte enhancer. Genes and Development 1994 8 10 1224 1234 2-s2.0-0028180070
58. Kahn B. B., Flier J. S., Obesity and insulin resistance. The Journal of Clinical Investigation 2000 106 4 473 481 10.1172/JCI10842
59. Lemberger T., Desvergne B., Wahli W., Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annual Review of Cell and Developmental Biology 1996 12 335 363 2-s2.0-0029731662 10.1146/annurev.cellbio.12.1.335
60. Hevener A. L., He W., Barak Y., Le J., Bandyopadhyay G., Olson P., Wilkes J., Evans R. M., Olefsky J., Muscle-specific Pparg deletion causes insulin resistance. Nature Medicine 2003 9 12 1491 1497 2-s2.0-0346027235 10.1038/nm956
61. Buchanan T. A., Xiang A. H., Peters R. K., Kjos S. L., Marroquin A., Goico J., Ochoa C., Tan S., Berkowitz K., Hodis H. N., Azen S. P., Preservation of pancreatic β -cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002 51 9 2796 2803 2-s2.0-0036724346
62. Xiang A. H., Peters R. K., Kjos S. L., Marroquin A., Goico J., Ochoa C., Kawakubo M., Buchanan T. A., Effect of pioglitazone on pancreatic β -cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006 55 2 517 522 2-s2.0-33644762010 10.2337/diabetes.55.02.06.db05- 1066
63. The DREAM Trial Investigators, Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. The Lancet 2006 368 9541 1096 1105 10.1016/S0140-6736(06)69420-8
64. Chiasson J. L., Josse R. G., Gomis R., Hanefeld M., Karasik A., Laakso M., Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. The Lancet 2002 359 9323 2072 2077 2-s2.0-0037097039 10.1016/S0140-6736(02)08905-5
65. Knowler W. C., Barrett-Connor E., Fowler S. E., Hamman R. F., Lachin J. M., Walker E. A., Nathan D. M., Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England Journal of Medicine 2002 346 6 393 403 2-s2.0-0037034257 10.1056/NEJMoa012512
66. Ribon V., Johnson J. H., Camp H. S., Saltiel A. R., Thiazolidinediones and insulin resistance: peroxisome proliferator-activated receptor γ activation stimulates expression of the CAP gene. Proceedings of the National Academy of Sciences of the United States of America 1998 95 25 14751 14756 2-s2.0-0032409985
67. Smith U., Gogg S., Johansson A., Olausson T., Rotter V., Svalstedt B., Thiazolidinediones (PPAR γ agonists) but not PPAR α agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes. FASEB Journal 2001 15 1 215 220 2-s2.0-0035172839 10.1096/fj.00-0020com
68. Mayerson A. B., Hundal R. S., Dufour S., Lebon V., Befroy D., Cline G. W., Enocksson S., Inzucchi S. E., Shulman G. I., Petersen K. F., The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002 51 3 797 802 2-s2.0-0036310037
69. Arner P., The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends in Endocrinology and Metabolism 2003 14 3 137 145 2-s2.0-0037732481 10.1016/S1043-2760(03)00024-9
70. Kahn C. R., Chen L., Cohen S. E., Unraveling the mechanism of action of thiazolidinediones. The Journal of Clinical Investigation 2000 106 11 1305 1307 2-s2.0-0033659881
71. Kharroubi I., Lee C. H., Hekerman P., Darville M. I., Evans R. M., Eizirik D. L., Cnop M., BCL-6: a possible missing link for anti-inflammatory PPAR- δ signalling in pancreatic beta cells. Diabetologia 2006 49 10 2350 2358 2-s2.0-33748489928 10.1007/s00125-006-0366-5
72. Welters H. J., McBain S. C., Tadayyon M., Scarpello J. H. B., Smith S. A., Morgan N. G., Expression and functional activity of PPAR γ in pancreatic β cells. British Journal of Pharmacology 2004 142 7 1162 1170 2-s2.0-4143051266 10.1038/sj.bjp.0705844
73. Ribon V., Printen J. A., Hoffman N. G., Kay B. K., Saltiel A. R., A novel, multifunctional c-Cbl binding protein in insulin receptor signaling in 3T3-L1 adipocytes. Molecular and Cellular Biology 1998 18 2 872 879 2-s2.0-0031594145
74. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., Mori Y., Ide T., Murakami K., Tsuboyama-Kasaoka N., Ezaki O., Akanuma Y., Gavrilova O., Vinson C., Reitman M. L., Kagechika H., Shudo K., Yoda M., Nakano Y., Tobe K., Nagai R., Kimura S., Tomita M., Froguel P., Kadowaki T., The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Medicine 2001 7 8 941 946 2-s2.0-17944365228 10.1038/90984
75. Berger J., Tanen M., Elbrecht A., Hermanowski-Vosatka A., Moller D. E., Wright S. D., Thieringer R., Peroxisome proliferator-activated receptor- γ ligands inhibit adipocyte 11 β -hydroxysteroid dehydrogenase Type 1 expression and activity. The Journal of Biological Chemistry 2001 276 16 12629 12635 2-s2.0-0035918143 10.1074/jbc.M003592200
76. Rangwala S. M., Rhoades B., Shapiro J. S., Rich A. S., Kim J. K., Shulman G. I., Kaestner K. H., Lazar M. A., Genetic modulation of PPAR γ phosphorylation regulates insulin sensitivity. Developmental Cell 2003 5 4 657 663 2-s2.0-0141920726 10.1016/S1534-5807(03)00274-0
77. Jason J. R., Suia X., Hookera S. P., LaMonteb M. L., Matthewsc C. E., Handa G. A., Blaira S. N., Metabolic syndrome and risk of cancer mortality in men. European Journal of Cancer 2009 45 10 1831 1838 10.1016/j.ejca.2009.01.031
78. Hsu I. R., Kim S. P., Kabir M., Bergman R. N., Metabolic syndrome, hyperinsulinemia, and cancer. The American Journal of Clinical Nutrition 2007 86 3 s867 s871
79. Cowey S., Hardy R. W., The metabolic syndrome: a high-risk state for cancer? The American Journal of Pathology 2006 169 5 1505 1522 2-s2.0-33947653911 10.2353/ajpath.2006.051090
80. Saltiel A. R., Kahn C. R., Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001 414 6865 799 806 2-s2.0-0035856949 10.1038/414799a
81. Furtado L. M., Somwar R., Sweeney G., Niu W., Klip A., Activation of the glucose transporter GLUT4 by insulin. Biochemistry and Cell Biology 2002 80 5 569 578 10.1139/o02-156
82. Watson R. T., Kanzaki M., Pessin J. E., Regulated membrane trafficking of the insulin-responsive glucose transporter 4 in adipocytes. Endocrine Reviews 2004 25 2 177 204 2-s2.0-10344236432 10.1210/er.2003-0011
83. Standaert M. L., Kanoh Y., Sajan M. P., Bandyopadhyay G., Farese R. V., Cbl, IRS-1, and IRS-2 mediate effects of rosiglitazone on PI3K, PKC- and glucose transport in 3T3/L1 adipocytes. Endocrinology 2002 143 5 1705 1716 2-s2.0-0036225280 10.1210/en.143.5.1705
84. Kramer D., Shapiro R., Adler A., Bush E., Rondinone C. M., Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of zucker rats. Metabolism 2001 50 11 1294 1300 2-s2.0-0035655245 10.1053/meta.2001.27202
85. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., Mori Y., Ide T., Murakami K., Tsuboyama-Kasaoka N., Ezaki O., Akanuma Y., Gavrilova O., Vinson C., Reitman M. L., Kagechika H., Shudo K., Yoda M., Nakano Y., Tobe K., Nagai R., Kimura S., Tomita M., Froguel P., Kadowaki T., The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Medicine 2001 7 8 941 946 2-s2.0-17944365228 10.1038/90984
86. Welters H. J., McBain S. C., Tadayyon M., Scarpello J. H. B., Smith S. A., Morgan N. G., Expression and functional activity of PPAR γ in pancreatic β cells. British Journal of Pharmacology 2004 142 7 1162 1170 2-s2.0-4143051266 10.1038/sj.bjp.0705844
87. Kota B. P., Huang T. H. W., Roufogalis B. D., An overview on biological mechanisms of PPARs. Pharmacological Research 2005 51 2 85 94 2-s2.0-11144310564 10.1016/j.phrs.2004.07.012
88. Schmidt M. V., Brüne B., Von Knethen A., The nuclear hormone receptor PPAR γ as a therapeutic target in major diseases. The Scientific World Journal 2010 10 2181 2197 2-s2.0-78650286735 10.1100/tsw.2010.213
89. Jiang C., Ting A. T., Seed B., PPAR- γ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998 391 6662 82 86 2-s2.0-0031888958 10.1038/34184
90. Poynter M. E., Daynes R. A., Peroxisome proliferator-activated receptor α activation modulates cellular redox status, represses nuclear factor- B signaling, and reduces inflammatory cytokine production in aging. The Journal of Biological Chemistry 1998 273 49 32833 32841 2-s2.0-0032484123 10.1074/jbc.273.49.32833
91. Chinetti G., Griglio S., Antonucci M., Torra I. P., Delerive P., Majd Z., Fruchart J. C., Chapman J., Najib J., Staels B., Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. The Journal of Biological Chemistry 1998 273 40 25573 25580 2-s2.0-0032475922 10.1074/jbc.273.40.25573
92. Law R. E., Meehan W. P., Xi X. P., Graf K., Wuthrich D. A., Coats W., Faxon D., Hsueh W. A., Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. The Journal of Clinical Investigation 1996 98 8 1897 1905 2-s2.0-0029861097
93. Law R. E., Goetze S., Xi X. P., Jackson S., Kawano Y., Demer L., Fishbein M. C., Meehan W. P., Hsueh W. A., Expression and function of PPAR γ in rat and human vascular smooth muscle cells. Circulation 2000 101 11 1311 1318 2-s2.0-0034696412
94. Marx N., Schönbeck U., Lazar M. A., Libby P., Plutzky J., Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circulation Research 1998 83 11 1097 1103 2-s2.0-0344333464
95. Daynes R. A., Jones D. C., Emerging roles of PPARs in inflammation and immunity. Nature Reviews Immunology 2002 2 10 748 759 10.1038/nri912
96. Delerive P., Fruchart J. C., Staels B., Peroxisome proliferator-activated receptors in inflammation control. Journal of Endocrinology 2001 169 3 453 459 2-s2.0-0034965596 10.1677/joe.0.1690453
97. Murakami K., Tobe K., Ide T., Mochizuki T., Ohashi M., Akanuma Y., Yazaki Y., Kadowaki T., A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor- α (PPAR- α) and PPAR- γ. Effect of PPAR- α activation on abnormal lipid metabolism in liver of Zucker fatty rats. Diabetes 1998 47 12 1841 1847 2-s2.0-0031793850
98. Wang Y., Porter W. W., Suh N., Honda T., Gribble G. W., Leesnitzer L. M., Plunket K. D., Mangelsdorf D. J., Blanchard S. G., Willson T. M., Sporn M. B., A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor γ Molecular Endocrinology 2000 14 10 1550 1556 2-s2.0-0033777347
99. Wright H. M., Clish C. B., Mikami T., Hauser S., Yanagi K., Hiramatsu R., Serhan C. N., Spiegelman B. M., A synthetic antagonist for the peroxisome proliferator-activated receptor γ inhibits adipocyte differentiation. The Journal of Biological Chemistry 2000 275 3 1873 1877 2-s2.0-0034695479 10.1074/jbc.275.3.1873
100. Mukherjee R., Hoener P. A., Jow L., Bilakovics J., Klausing K., Mais D. E., Faulkner A., Croston G. E., Paterniti J. R., A selective peroxisome proliferator-activated receptor- γ (PPAR γ) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes. Molecular Endocrinology 2000 14 9 1425 1433 2-s2.0-0033766035
101. Hwang B. Y., Lee J. H., Nam J. B., Kim H. S., Hong Y. S., Lee J. J., Two new furanoditerpenes from Saururus chinenesis and their effects on the activation of peroxisome proliferator-activated receptor γ Journal of Natural Products 2002 65 4 616 617 2-s2.0-0036239765 10.1021/np010440j
102. Liang Y. C., Tsai S. H., Tsai D. C., Lin-Shiau S. Y., Lin J. K., Suppression of inducible cyclooxygenase and nitric oxide synthase through activation of peroxisome proliferator-activated receptor- γ by flavonoids in mouse macrophages. FEBS Letters 2001 496 1 12 18 2-s2.0-0035805144 10.1016/S0014-5793(01)02393-6
103. y mice. Bioorganic and Medicinal Chemistry Letters 2003 13 24 4267 4272 2-s2.0-0344496057 10.1016/j.bmcl.2003.09.052
104. Braissant O., Foufelle F., Scotto C., Dauça M., Wahli W., Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR- α-β and-γ in the adult rat. Endocrinology 1996 137 1 354 366 2-s2.0-0030047806 10.1210/en.137.1.354
105. Auboeuf D., Rieusset J., Fajas L., Vallier P., Frering V., Riou J. P., Staels B., Auwerx J., Laville M., Vidal H., Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor- α in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997 46 8 1319 1327 2-s2.0-0030747895
106. Inoue I., Shino K., Noji S., Awata T., Katayama S., Expression of peroxisome proliferator-activated receptor α (PPAR α) in primary cultures of human vascular endothelial cells. Biochemical and Biophysical Research Communications 1998 246 2 370 374 2-s2.0-0032546485 10.1006/bbrc.1998.8622
107. Diep Q. N., Touyz R. M., Schiffrin E. L., Docosahexaenoic acid, a peroxisome proliferator-activated receptor- α ligand, induces apoptosis in vascular smooth muscle cells by stimulation of p38: mitogen-activated protein kinase. Hypertension 2000 36 5 851 855 2-s2.0-0033679198
108. Chinetti G., Griglio S., Antonucci M., Activation of proliferator activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. The Journal of Biological Chemistry 1998 273 25573 25580 10.1074/jbc.273.40.25573
109. Staels B., Koenig W., Habib A., Merval R., Lebret M., Torra I. P., Delerive P., Fadel A., Chinetti G., Fruchart J. C., Najib J., Maclouf J., Tedgui A., Activation of human aortic smooth-muscle cells is inhibited by PPAR α but not by PPAR γ activators. Nature 1998 393 6687 790 793 2-s2.0-0032565868 10.1038/31701
110. Reddy J. K., Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal beta-oxidation, PPAR α and steatohepatitis. American Journal of Physiology 2001 281 6 G1333 G1339
111. Yu S., Rao S., Reddy J. K., Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis. Current Molecular Medicine 2003 3 6 561 572 2-s2.0-0141828972 10.2174/1566524033479537
112. Leone T. C., Weinheimer C. J., Kelly D. P., A critical role for the peroxisome proliferator-activated receptor α (PPAR α) in the cellular fasting response: the PPAR α -null mouse as a model of fatty acid oxidation disorders. Proceedings of the National Academy of Sciences of the United States of America 1999 96 13 7473 7478 10.1073/pnas.96.13.7473
113. Li A., Palinski W., Peroxisome proliferator-acitivated receptors: how theirs effects on macrophages can lead to the development of a new drug therapy againg arterosclerosis. Annual Review of Pharmacology and Toxicology 2006 46 1 39 10.1146/annurev.pharmtox.46.120604.141247
114. Motojima K., Passilly P., Peters J. M., Gonzalez F. J., Latruffe N., Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor α and γ activators in a tissue- and inducer-specific manner. The Journal of Biological Chemistry 1998 273 27 16710 16714 2-s2.0-0032479423 10.1074/jbc.273.27.16710
115. Guan Y., Zhang Y., Breyer M. D., The role of PPARs in the transcriptional control of cellular preocesses. Drug News Perspectno 2002 15 3 147 154 10.1358/dnp.2002.15.3.840011
116. Neve B. P., Fruchart J. C., Staels B., Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochemical Pharmacology 2000 60 8 1245 1250 2-s2.0-0034668205 10.1016/S0006-2952(00)00430-5
117. Plutzky J., Emerging concepts in metabolic abnormalities associated with coronary artery disease. Current Opinion in Cardiology 2000 15 6 416 421 2-s2.0-0033695265 10.1097/00001573-200011000-00008
118. Vu-Dac N., Schoonjans K., Laine B., Fruchart J. C., Auwerx J., Staels B., Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. The Journal of Biological Chemistry 1994 269 49 31012 31018 2-s2.0-0028036723
119. Vu-Dac N., Schoonjans K., Kosykh V., Dallongeville J., Fruchart J. C., Staels B., Auwerx J., Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. The Journal of Clinical Investigation 1995 96 2 741 750 2-s2.0-0029119082
120. Schoonjans K., Peinado-Onsurbe J., Lefebvre A. M., Heyman R. A., Briggs M., Deeb S., Staels B., Auwerx J., PPAR α and PPAR γ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO Journal 1996 15 19 5336 5348 2-s2.0-0029791412
121. Djouadi F., Weinheimer C. J., Saffitz J. E., Pitchford C., Bastin J., Gonzalez F. J., Kelly D. P., A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator-activated receptor α -deficient mice. The Journal of Clinical Investigation 1998 102 6 1083 1091 2-s2.0-0032530765
122. Maida A., Lamont B. J., Cao X., Drucker D. J., Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor- α in mice. Diabetologia 2011 54 2 339 349 2-s2.0-78951476273 10.1007/s00125-010-1937-z
123. Seedorf U., Assmann G., The role of PPAR α in obesity. Nutrition, Metabolism & Cardiovascular Diseases 2001 11 3 189 194
124. Costet P., Legendre C., Moré J., Edgar A., Galtier P., Pineau T., Peroxisome proliferator-activated receptor α -isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. The Journal of Biological Chemistry 1998 273 45 29577 29585 2-s2.0-0032491614 10.1074/jbc.273.45.29577
125. Vázquez M., Merlos M., Adzet T., Laguna J. C., Decreased susceptibility to copper-induced oxidation of rat-lipoproteins after fibrate treatment: influence of fatty acid composition. British Journal of Pharmacology 1996 117 6 1155 1162 2-s2.0-0029883688
126. Kim B. H., Won Y. S., Kim E. Y., Yoon M., Nam K. T., Oh G. T., Kim D. Y., Phenotype of peroxisome proliferator-activated receptor- α (PPAR α) deficient mice on mixed background fed high fat diet. Journal of Veterinary Science 2003 4 3 239 244 2-s2.0-1542707159
127. Aasum E., Belke D. D., Severson D. L., Riemersma R. A., Cooper M., Andreassen M., Larsen T. S., Cardiac function and metabolism in type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR- α activator. American Journal of Physiology 2002 283 3 H949 H957 2-s2.0-0036352058
128. Koh E. H., Kim M. S., Park J. Y., Kim H. S., Youn J. Y., Park H. S., Youn J. H., Lee K. U., Peroxisome proliferator-activated receptor (PPAR)- α activation prevents diabetes in OLETF rats: comparison with PPAR- γ activation. Diabetes 2003 52 9 2331 2337 2-s2.0-0042822095 10.2337/diabetes.52. 9.2331
129. Park C. W., Zhang Y., Fan X. F., Davis L., Capdevila J. H., Guan Y., Breyer M. D., A PPAR α agonist improves diabetic nephropathy in db/db mice. Journal of the American Society of Nephrology 2003 14 393A
130. Panz V. R., Wing J. R., Raal F. J., Kedda M. A., Joffe B. I., Improved glucose tolerance after effective lipid-lowering therapy with bezafibrate in a patient with lipoatrophic diabetes mellitus: a putative role for Randle's cycle in its pathogenesis? Clinical Endocrinology 1997 46 3 365 368 2-s2.0-0031002711
131. Chinetti G., Gbaguidi F. G., Griglio S., Mallat Z., Antonucci M., Poulain P., Chapman J., Fruchart J. C., Tedgui A., Najib-Fruchart J., Staels B., CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 2000 101 20 2411 2417 2-s2.0-0034705071
132. Chinetti G., Lestavel S., Bocher V., Remaley A. T., Neve B., Torra I. P., Teissier E., Minnich A., Jaye M., Duverger N., Brewer H. B., Fruchart J. C., Clavey V., Staels B., PPAR- α and PPAR- γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nature Medicine 2001 7 1 53 58 2-s2.0-0035138625 10.1038/83348
133. Knight B. L., Patel D. D., Humphreys S. M., Wiggins D., Gibbons G. F., Inhibition of cholesterol absorption associated with a PPAR α -dependent increase in ABC binding cassette transporter A1 in mice. Journal of Lipid Research 2003 44 11 2049 2058 2-s2.0-0344236149 10.1194/jlr.M300042-JLR200
134. Duezt H., Chao Y. S., Hernandez M., Torpier G., Poulain P., Mundt S., Mallat Z., Teissier E., Burton C. A., Tedgui A., Fruchart J. C., Fiévet C., Wright S. D., Staels B., Reduction of atherosclerosis by the peroxisome proliferator-activated receptor α agonist fenofibrate in mice. The Journal of Biological Chemistry 2002 277 50 48051 48057 2-s2.0-2242436246 10.1074/jbc.M206966200
135. Peters J. M., Lee S. S. T., Li W., Ward J. M., Gavrilova O., Everett C., Reitman M. L., Hudson L. D., Gonzalez F. J., Growths, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β (δ). Molecular and Cellular Biology 2000 20 14 5119 5128 2-s2.0-0033625677 10.1128/MCB.20.14.5119-5128.2000
136. Barak Y., Liao D., He W., Ong E. S., Nelson M. C., Olefsky J. M., Boland R., Evans R. M., Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America 2002 99 1 303 308 2-s2.0-0037039374 10.1073/pnas.012610299
137. Rubins H. B., Robins S. J., Collins D., Fye C. L., Anderson J. W., Elam M. B., Faas F. H., Linares E., Schaefer E. J., Schectman G., Wilt T. J., Wittes J., Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. The New England Journal of Medicine 1999 341 6 410 418 2-s2.0-0033527030 10.1056/NEJM199908053410604
138. Rubins H. B., Robins S. J., Conclusions from the VA-HIT study. American Journal of Cardiology 2000 86 5 543 544 10.1016/S0002-9149(00)01010-9
139. Robins S. J., Rubins H. B., Faas F. H., Schaefer E. J., Elam M. B., Anderson J. W., Collins D., Insulin resistance and cardiovascular events with low HDL cholesterol: the veterans affairs HDL intervention trial (VA-HIT). Diabetes Care 2003 26 5 1513 1517 2-s2.0-0042669791 10.2337/diacare.26.5.1513
140. Staels B., Koenig W., Habib A., Merval R., Lebret M., Torra I. P., Delerive P., Fadel A., Chinetti G., Fruchart J. C., Najib J., Maclouf J., Tedgui A., Activation of human aortic smooth-muscle cells is inhibited by PPAR α but not by PPAR γ activators. Nature 1998 393 6687 790 793 2-s2.0-0032565868 10.1038/31701
141. Marx N., Sukhova G. K., Collins T., Libby P., Plutzky J., PPAR α activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999 99 24 3125 3131 2-s2.0-0033594810
142. Goya K., Sumitani S., Xu X., Kitamura T., Yamamoto H., Kurebayashi S., Saito H., Kouhara H., Kasayama S., Kawase I., Peroxisome proliferator-activated receptor α agonists increase nitric oxide synthase expression in vascular endothelial cells. Arteriosclerosis, Thrombosis, and Vascular Biology 2004 24 4 658 663 2-s2.0-11144355198 10.1161/01.ATV.0000118682.58708.78
143. Colville-Nash P., Willis D., Papworth J., Freemantle C., Lam C., Andrews G., Willoughby D., The peroxisome proliferator-activated receptor α activator, Wy14,643, is anti-inflammatory in vivo. Inflammopharmacology 2005 12 5-6 493 504 2-s2.0-27744557391 10.1163/156856005774382724
144. Berger J., Leibowitz M. D., Doebber T. W., Elbrecht A., Zhang B., Zhou G., Biswas C., Cullinan C. A., Hayes N. S., Li Y., Tanen M., Ventre J., Wu M. S., Berger G. D., Mosley R., Marquis R., Santini C., Sahoo S. P., Tolman R. L., Smith R. G., Moller D. E., Novel peroxisome proliferator-activated receptor (PPAR) γ and PPAR δ ligands produce distinct biological effects. The Journal of Biological Chemistry 1999 274 10 6718 6725 10.1074/jbc.274.10.6718
145. Bishop-Bailey D., Peroxisome proliferator-activated receptors in the cardiovascular system. British Journal of Pharmacology 2000 129 5 823 833 2-s2.0-0034057069
146. Lim H., Dey S. K., PPAR δ functions as a prostacyclin receptor in blastocyst implantation. Trends in Endocrinology and Metabolism 2000 11 4 137 142 2-s2.0-0034094324 10.1016/S1043-2760(00)00243-5
147. Martens F. M. A. C., Visseren F. L. J., Lemay J., De Koning E. J. P., Rabelink T. J., Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002 62 10 1463 1480 2-s2.0-0036076907
148. Duval C., Chinetti G., Trottein F., Fruchart J. C., Staels B., The role of PPARs in atherosclerosis. Trends in Molecular Medicine 2002 8 9 422 430 2-s2.0-0036727448 10.1016/S1471-4914(02)02385-7
149. Bishop-Bailey D., Wray J., Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation. Prostaglandins and Other Lipid Mediators 2003 71 1-2 1 22 2-s2.0-0037389926 10.1016/S0090-6980(03)00003-0
150. Shearer B. G., Steger D. J., Way J. M., Stanley T. B., Lobe D. C., Grillot D. A., Iannone M. A., Lazar M. A., Willson T. M., Billin A. N., Identification and characterization of a selective peroxisome proliferator-activated receptor β / δ (NR1C2) antagonist. Molecular Endocrinology 2008 22 2 523 529 2-s2.0-38749152401 10.1210/me.2007-0190
151. Leibowitz M. D., Fievet C., Hennuyer N., Peinado-Onsurbe J., Duez H., Bergera J., Cullinan C. A., Sparrow C. P., Baffic J., Berger G. D., Santini C., Marquis R. W., Tolman R. L., Smith R. G., Moller D. E., Auwerx J., Activation of PPAR δ alters lipid metabolism in db/db mice. FEBS Letters 2000 473 3 333 336 10.1016/S0014-5793(00)01554-4
152. Oliver W. R. Jr, Shenk J. L., Snaith M. R., Russell C. S., Plunket K. D., Bodkin N. L., Lewis M. C., Winegar D. A., Sznaidman M. L., Lambert M. H., Xu H. E., Sternbach D. D., Kliewer S. A., Hansen B. C., Willson T. M., A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proceedings of the National Academy of Sciences of the United States of America 2001 98 9 5306 5311 2-s2.0-0035942162 10.1073/pnas.091021198
153. Tanaka T., Yamamoto J., Iwasaki S., Asaba H., Hamura H., Ikeda Y., Activation of peroxisome proliferator-activated receptor delta induces fatty acid β -oxidation in skeletal muscle and attenuates metabolic syndrome. Proceedings of the National Academy of Sciences of the United States of America 2003 100 26 15924 15929 10.1073/pnas.0306981100
154. Wang Y. X., Lee C. H., Tiep S., Yu R. T., Ham J., Kang H., Evans R. M., Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity. Cell 2003 113 2 159 170 2-s2.0-0037453718 10.1016/S0092- 8674(03)00269-1
155. Luquet S., Lopez-Soriano J., Holst D., Fredenrich A., Melki J., Rassoulzadegan M., Grimaldi P. A., Peroxisome proliferator-activated receptor δ controls muscle development and oxidative capability. FASEB Journal 2003 17 15 2299 2301 2-s2.0-0642303113 10.1096/fj.03-0269fje
156. Wang Y. X., Zhang C. L., Yu R. T., Cho H. K., Nelson M. C., Bayuga-Ocampo C. R., Ham J., Kang H., Evans R. M., Regulation of muscle fiber type and running endurance by PPAR δ PLoS Biology 2004 2 10 2-s2.0-8844276054 10.1371/journal.pbio.0020294
157. Dressel U., Allen T. L., Pippal J. B., Rohde P. R., Lau P., Muscat G. E. O., The peroxisome proliferator-activated receptor β / δ agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Molecular Endocrinology 2003 17 12 2477 2493 2-s2.0-0346849699 10.1210/me.2003-0151
158. Cohen G., Riahi Y., Shamni O., Guichardant M., Chatqilialoqlu C., Ferreri C., Kaiser N., Sasson S., Role of lipid peroxidation and PPAR- δ in amplifying glucose-stimulated insulin secretion. Diabetes 2011 60 11 2830 2842 10.2337/db11-0347
159. Serrana-Marco L., Rodríguez-Calvo R., El Kochairi I., Palomer X., Michalik L., Wahli W., Vázquez-Carrera M. V., Activation of peroxisome proliferator-activated receptor- β /- δ (PPAR- β /- δ) ameliorates insulin signaling and reduces SOCS3 levels by inhibiting STAT3 in interleukin-6-stimulated adipocytes. Diabetes 2011 60 7 1990 11999 10.2337/db10-0704
160. Smeets P. J., Teunissen B. E. J., Planavila A., Inflammatory pathways are activated during cardiomyocyte hypertrophy and attenuated by peroxisome proliferator-activated receptors PPAR α and PPAR δ The Journal of Biological Chemistry 2008 283 29109 29118 10.1074/jbc.M802143200
161. Sznaidman M. L., Haffner C. D., Maloney P. R., Fivush A., Chao E., Goreham D., Sierra M. L., LeGrumelec C., Xu H. E., Montana V. G., Lambert M. H., Willson T. M., Oliver W. R., Sternbach D. D., Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPAR δ)-synthesis and biological activity. Bioorganic and Medicinal Chemistry Letters 2003 13 9 1517 1521 2-s2.0-12444289447 10.1016/S0960-894X(03)00207-5
162. Berger J., Leibowitz M. D., Doebber T. W., Elbrecht A., Zhang B., Zhou G., Biswas C., Cullinan C. A., Hayes N. S., Li Y., Tanen M., Ventre J., Wu M. S., Berger G. D., Mosley R., Marquis R., Santini C., Sahoo S. P., Tolman R. L., Smith R. G., Moller D. E., Novel peroxisome proliferatoractivated receptor (PPAR) γ and PPAR δ ligands produce distinct biological effects. The Journal of Biological Chemistry 1999 274 6718 6725 10.1074/jbc.274.10.6718
163. Ding G., Cheng L., Qin Q., PPAR δ modulates lipo polysaccharide-induced TNF α inflammation signaling in cultured cardiomyocytes. Journal of Molecular and Cellular Cardiology 2006 40 6 821 828
164. Álvarez-Guardiaa D., Palomera X., Colla T., PPAR β / δ activation blocks lipid-induced inflammatory pathways in mouse heart and human cardiac cells. Biochimica et Biophysica Acta 2011 1811 2 59 67 10.1016/j.bbalip.2010.11.002
165. Caglayan E., Stauber B., Collins A. R., Lyon C. J., Yin F., Liu J., Rosenkranz S., Erdmann E., Peterson L. E., Ross R. S., Tangirala R. K., Hsueh W. A., Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor γ in cardiac fibrosis. Diabetes 2008 57 9 2470 2479 2-s2.0-52749098189 10.2337/db07-0924
166. -/- mice. Atherosclerosis 2005 181 1 29 37 2-s2.0-20444378931 10.1016/j. atherosclerosis.2004.12.028
167. Lee C. H., Chawla A., Urbiztondo N., Transcriptional repression of atherogenic inflammation: modulation by PPAR δ Science 2003 302 5644 453 457 10.1126/science.1087344
168. Beckman J. A., Creager M. A., Libby P., Diabetes and atherosclerosis epidemiology, pathophysiology, and management. Journal of the American Medical Association 2002 287 19 2570 2581 2-s2.0-0037092995
169. Moraes L. A., Spyridon M., Kaiser W. J., Jones C. I., Sage T., Atherton R. E. L., Gibbins J. M., Non-genomic effects of PPAR γ ligands: inhibition of GPVI-stimulated platelet activation. Journal of Thrombosis and Haemostasis 2010 8 3 577 587 2-s2.0-77949292613 10.1111/j.1538-7836.2009.03732.x
170. Yessoufou A., Wahli W., Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels. Swiss Medical Weekly 2010 140 w13071 2-s2.0-79952064509 10.4414/smw.2010.13071
171. Ali F. Y., Davidson S. J., Moraes L. A., Traves S. L., Paul-Clark M., Bishop-Bailey D., Warner T. D., Mitchell J. A., Role of nuclear receptor signaling in platelets: antithrombotic effects of PPAR β FASEB Journal 2006 20 2 326 328 2-s2.0-33644883024 10.1096/fj.05-4395fje
172. Gibbins J. M., Platelet adhesion signalling and the regulation of thrombus formation. Journal of Cell Science 2004 117 16 3415 3425 2-s2.0-4444260266 10.1242/jcs.01325
173. Nieswandt B., Watson S. P., Platelet-collagen interaction: is GPVI the central receptor? Blood 2003 102 2 449 461 2-s2.0-0038494921 10.1182/blood-2002-12-3882
174. Nieuwenhuis H. K., Akkerman J. W. N., Houdijk W. P. M., Sixma J. J., Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. Nature 1985 318 6045 470 472 2-s2.0-0022353697
175. Chou T. C., Shih C. Y., Chen Y. T., Inhibitory effect of α -lipoic acid on platelet aggregation is mediated by PPARs. Journal of Agricultural and Food Chemistry 2011 59 7 3050 3059 2-s2.0-79953890808 10.1021/jf103940u
176. Lee Y. J., Lee Y. M., Lee C. K., Jung J. K., Han S. B., Hong J. T., Therapeutic applications of compounds in the Magnolia family. Pharmacology and Therapeutics 2011 130 2 157 176 2-s2.0-79953654775 10.1016/j.pharmthera.2011.01. 010
177. Teng C. M., Chen C. C., Ko F. N., Lee L. G., Huang T. F., Chen Y. P., Hsu H. Y., Two antiplatelet agents from Magnolia officinalis. Thrombosis Research 1988 50 6 757 765 2-s2.0-0023788461
178. Shih C. Y., Chou T. C., The antiplatelet activity of magnolol is mediated by PPAR- β / γ Biochemical Pharmacology 2012 84 6 793 803 10.1016/j.bcp.2012.06.022
179. Pula G., Crosby D., Baker J., Poole A. W., Functional interaction of protein kinase C α with the tyrosine kinases Syk and Src in human platelets. The Journal of Biological Chemistry 2005 280 8 7194 7205 2-s2.0-14844302394 10.1074/jbc.M409212200
180. 2+-induced platelet aggregation. The Journal of Biological Chemistry 2003 278 29 26374 26379 2-s2.0-0038712739 10.1074/jbc.M212407200
181. Moraes L. A., Spyridon M., Kaiser W. J., Jones C. I., Sage T., Atherton R. E. L., Gibbins J. M., Non-genomic effects of PPAR γ ligands: inhibition of GPVI-stimulated platelet activation. Journal of Thrombosis and Haemostasis 2010 8 3 577 587 2-s2.0-77949292613 10.1111/j.1538-7836.2009.03732.x
182. Michalik L., Desvergne B., Dreyer C., Gavillet M., Laurini R. N., Wahli W., PPAR expression and function during vertebrate development. International Journal of Developmental Biology 2002 46 1 105 114 2-s2.0-0036005782
183. Motojima K., Peroxisome proliferator-activated receptor (PPAR): structure, mechanisms of activation and diverse functions. Cell Structure and Function 1993 18 5 267 277 2-s2.0-0027738795
184. Tyagi S., Gupta P., Saini A. S., Kaushal C., Sharma S., The peroxisome proliferator-activated receptor: a family of nuclear receptors role in various diseases. Journal of Advanced Pharmaceutical Technology and Research 2011 2 4 236 2340 10.4103/2231-4040.90879
185. Marx N., Duez H., Fruchart J. C., Staels B., Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circulation Research 2004 94 9 1168 1178 2-s2.0-2442711384 10.1161/01.RES.0000127122.22685.0A
186. Park J. I., Kwak J. Y., The role of peroxisome proliferator-activated receptors in colorectal cancer. PPAR Research 2012 2012 12 876418 10.1155/2012/876418
187. Sturm S., Bentley D., Jordan P., Russell-Yarde F., Ruf T., No evidence of QT prolongation with supratherapeutic doses of aleglitazar. Journal of Cardiovascular Pharmacology 2012 59 3 288 2889 10.1097/FJC.0b013e3182411e67
188. Henry R. R., Lincoff A. M., Mudaliar S., Rabbia M., Chognot C., Herz M., Effect of the dual peroxisome proliferator-activated receptor- α / γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. The Lancet 2009 374 9684 126 135 2-s2.0-67649839953 10.1016/S0140-6736(09)60870-9
189. Herz M., Gaspari F., Perico N., Viberti G., Urbanowska T., Rabbia M., Wieczorek Kirk D., Effects of high dose aleglitazar on renal function in patients with type 2 diabetes. International Journal of Cardiology 2011 151 2 136 142 10.1016/j.ijcard.2010.08.037.
190. Foley-Comer A. J., Young A. M., Russell-Yarde F., Jordan P., Aleglitazar, a balanced PPAR α / γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin. Expert Opinion on Investigational Drugs 2011 20 1 3 12 2-s2.0-78650262962 10.1517/13543784.2010.539559
191. Wei J., Tang Q., Liu L., Bin J., Combination of peroxisome proliferator-activated receptor α / γ agonists may benefit type 2 diabetes patients with coronary artery disease through inhibition of inflammatory cytokine secretion. Experimental and Therapeutic Medicine 2013 5 3 783 788
192. Choi Y. J., Roberts B. K., Wang X., Geaney J. C., Naim S., Wojnoonski K., Karpf D. B., Krauss R. M., Effects of the PPAR- δ agonist MBX-8025 on atherogenic dyslipidemia. Atherosclerosis 220 2 470 4706 10.1016/j. atherosclerosis.2011.10.029
193. Olson E. J., Pearce G. L., Jones N. P., Sprecher D. L., Lipid effects of peroxisome proliferator-activated receptor-Δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology 2012 32 9 2289 2894 10.1161/ATVBAHA.112.247890
194. Bojic L. A., Sawyez C. G., Telford D. E., Edwards J. Y., Hegele R. A., Huff M. W., Activation of peroxisome proliferator-activated receptor δ inhibits human macrophage foam cell formation and the inflammatory response induced by very low-density lipoprotein. Arteriosclerosis, Thrombosis, and Vascular Biology 2012 32 12 2919 29128 10.1161/ATVBAHA.112.255208
195. Huo Y., Schober A., Forlow S. B., Smith D. F., Hyman M. C., Jung S., Littman D. R., Weber C., Ley K., Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nature Medicine 2003 9 1 61 67 2-s2.0-0037231665 10.1038/nm810
196. Sidhu J. S., Cowan D., Tooze J. A., Kaski J. C., Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease. American Heart Journal 2004 147 6 e25 2-s2.0-4544235535
197. Khanolkar M. P., Morris R. H. K., Thomas A. W., Bolusani H., Roberts A. W., Geen J., Jackson S. K., Evans L. M., Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus-an effect probably mediated by direct platelet PPAR γ activation. Atherosclerosis 2008 197 2 718 724 2-s2.0-40949098983 10.1016/j.atherosclerosis.2007.07.020
198. 2+-ATPase and -calpain activity are altered in type 2 diabetes mellitus and restored by rosiglitazone. Circulation 2008 117 1 52 60 2-s2.0-37349104971 10.1161/CIRCULATIONAHA.107.719807